Literature DB >> 19357726

The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.

Ponsiano Ocama1, Michael Katwere, Theresa Piloya, Jordan Feld, Kenneth C Opio, Andrew Kambugu, Elly Katabira, David Thomas, Robert Colebunders, Allan Ronald.   

Abstract

BACKGROUND: Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections.
OBJECTIVE: To describe the spectrum of liver diseases in HIV-infected patients attending an HIV clinic in Kampala, Uganda.
METHOD: Consecutive patients presenting with jaundice, right upper quadrant pain with fever or malaise, ascites and/or tender hepatomegaly were recruited and underwent investigations to evaluate the cause of their liver disease.
RESULTS: Seventy-seven consecutive patients were recruited over an eleven month period. Of these, 23 (30%) had increased transaminases because of nevirapine (NVP) and/or isoniazid (INH) hepatotoxicity. Although 14 (61%) patients with drug-induced liver disease presented with jaundice, all recovered with drug discontinuation. Hepatitis B surface antigen was positive in 11 (15%) patients while anti-hepatitis C antibody was reactive in only 2 (3%). Probable granulomatous hepatitis due to tuberculosis was diagnosed in 7 (9%) patients and all responded to anti-TB therapy. Other diagnoses included alcoholic liver disease, AIDS cholangiopathy, hepatocellular carcinoma, schistosomiasis, haemangioma and hepatic adenoma. Twelve (16%) patients died during follow-up of which 7 (9%) died because of liver disease.
CONCLUSION: Drug history, liver enzyme studies, ultrasound, and hepatitis B and C investigations identified the probable etiology in 60 (78%) of 77 patients with HIV infection presenting with symptoms and/or signs of liver disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19357726      PMCID: PMC2408539     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  16 in total

1.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  Liver damage in HIV-infected patients.

Authors:  A M Wnuk
Journal:  Med Sci Monit       Date:  2001 Jul-Aug

3.  Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations.

Authors:  Javier Lizardi-Cervera; Luis E Soto Ramírez; Jorge Luis Poo; Misael Uribe
Journal:  Ann Hepatol       Date:  2005 Jul-Sep       Impact factor: 2.400

4.  Hepatitis B virus and hiv infections among patients in Mulago hospital.

Authors:  F N Nakwagala; M M Kagimu
Journal:  East Afr Med J       Date:  2002-02

5.  Prevalence of HCV and HCV/HIV co-infection among in-patients at the Kenyatta National Hospital.

Authors:  J W Karuru; G N Lule; M Joshi; O Anzala
Journal:  East Afr Med J       Date:  2005-04

6.  HCV and HIV co-infection in pregnant women attending St. Camille Medical Centre in Ouagadougou (Burkina Faso).

Authors:  J Simpore; D Ilboudo; A Samandoulougou; P Guardo; P Castronovo; Salvatore Musumeci
Journal:  J Med Virol       Date:  2005-02       Impact factor: 2.327

7.  Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.

Authors:  Christoph Stephan; Annemarie Berger; Amina Carlebach; Thomas Lutz; Markus Bickel; Stephan Klauke; Schlomo Staszewski; Martin Stuermer
Journal:  J Antimicrob Chemother       Date:  2005-11-03       Impact factor: 5.790

8.  Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.

Authors:  Rob van Hest; Hennie Baars; Sandra Kik; Paul van Gerven; Marie-Christine Trompenaars; Nico Kalisvaart; Sytze Keizer; Martien Borgdorff; Marlies Mensen; Frank Cobelens
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

9.  Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.

Authors:  Judith A Hahn; Marissa Maier; Jayne Byakika-Tusiime; Jessica H Oyugi; David R Bangsberg
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2007-06

10.  Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.

Authors:  Douglas T Dieterich; Patrick A Robinson; James Love; Jerry O Stern
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

View more
  18 in total

1.  Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV.

Authors:  C L Cherry; J S Affandi; B J Brew; J Creighton; S Djauzi; D J Hooker; D Imran; A Kamarulzaman; P Kamerman; J C McArthur; R D Moore; P Price; K Smyth; I L Tan; S Vanar; A Wadley; S L Wesselingh; E Yunihastuti
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda.

Authors:  P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas
Journal:  Int J STD AIDS       Date:  2010-08       Impact factor: 1.359

Review 3.  Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.

Authors:  Paul Kelly; Haroon Saloojee; Jennifer Y Chen; Raymond T Chung
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

4.  Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.

Authors:  Michael J Vinikoor; Edford Sinkala; Aggrey Mweemba; Arianna Zanolini; Lloyd Mulenga; Izukanji Sikazwe; Michael W Fried; Joseph J Eron; Gilles Wandeler; Benjamin H Chi
Journal:  Liver Int       Date:  2015-01-22       Impact factor: 5.828

5.  Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi.

Authors:  W Nakanga; P Patel; S Panjwani; N Kennedy; K Kawaza
Journal:  Malawi Med J       Date:  2015-09       Impact factor: 0.875

6.  Hepatitis B virus and HIV infection among patients with primary hepatocellular carcinoma in Kampala, Uganda.

Authors:  P Ocama; K C Opio; M Kagimu; E Seremba; H Wabinga; R Colebunders
Journal:  Afr Health Sci       Date:  2011-08       Impact factor: 0.927

7.  Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.

Authors:  Ponsiano Ocama; Emmanuel Seremba; Betty Apica; Kenneth Opio
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

8.  Atypical presentation of colon adenocarcinoma: a case report.

Authors:  Lynnette K Tumwine; Magid Kagimu; Ponsiano Ocama; Innocent Segamwenge; Noah Masiira-Mukasa; Dan Wamala; Otto Dworak; Christopher K Opio
Journal:  J Med Case Rep       Date:  2012-02-13

9.  Human immunodeficiency virus infection and the liver.

Authors:  Megan Crane; David Iser; Sharon R Lewin
Journal:  World J Hepatol       Date:  2012-03-27

Review 10.  Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature.

Authors:  David A Barr; Pravistadevi K Ramdial
Journal:  BMC Infect Dis       Date:  2012-10-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.